AMPX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AMPX is not a good buy right now for a beginner long-term investor, despite strong business momentum and bullish analyst sentiment. The stock has run up into a weak technical setup and the current setup is more suitable for traders than for an impatient long-term buyer. If you need to act now, the better call is to wait rather than buy at this level.
Price is 16.3464 after a volatile session. The trend structure is mixed: SMA_5 > SMA_20 > SMA_200 is bullish, but MACD histogram is -0.365 and negatively expanding, showing near-term momentum deterioration. RSI_6 at 26.827 suggests the stock is oversold and potentially due for a bounce, but that is not enough to override the weakening momentum. Price is currently below pivot 19.381 and only slightly above S1 16.718, indicating it is trading near support rather than in a clean uptrend. The pattern-based outlook also points to limited near-term upside. Overall technicals are short-term weak, medium-term constructive.
Q1 2026 revenue surged 152.89% YoY to $28.54M, and management raised full-year 2026 revenue guidance to at least $130M. Analyst commentary is broadly positive, with multiple firms raising price targets to the $20-$22 range and maintaining Buy/Overweight ratings. Recent catalysts include record quarterly revenue, strong demand for SiCore battery technology, progress toward NDAA-compliant production, and strategic interest from leveraged ETF product launches. Palisades Investment Partners also bought 369,476 shares, which is a bullish external signal.
Net income remains negative at -$5.046M and EPS is -$0.04, so profitability is not yet established. Gross margin fell to 20.11%, indicating weaker margin quality even as revenue grows. The stock recently saw a major regular-session decline of -27.40%, showing sharp adverse price action. Hedge funds and insiders are neutral, with no strong accumulation trend. There is no congress trading data and no impactful political buying/selling signal available.
In Q1 2026, Amprius delivered revenue of $28.54M, up 152.89% year over year, which is the main strength of the report and shows very strong top-line expansion. However, the company still posted a net loss of -$5.046M and EPS of -$0.04, both worse year over year, so the business is still in the scale-up phase. Gross margin of 20.11% declined sharply year over year, which suggests profitability quality is not yet improving at the same pace as sales. This was the latest quarter season reported: Q1 2026.
Analyst sentiment has improved noticeably over the last few months. Roth Capital, B. Riley, Cantor Fitzgerald, and Craig-Hallum all raised targets, mostly into the $20-$22 range, while keeping Buy/Overweight ratings. The recent trend is upward target revisions and positive commentary around execution, demand pipeline, and long-term growth visibility. Wall Street’s pros view is clearly bullish on the growth story; the cons view is that the stock is still loss-making and highly dependent on continued execution and commercialization progress. The overall analyst tone is positive, but the current price action does not offer a clean long-term entry for a beginner who wants to buy now.
